Organization | University of Colorado, Boulder

University of Colorado, Boulder Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4

Founded: Boulder CO United States (1876)

Organization Overview

First Clinical Trial

2005

NCT01408589

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Alternative names

Douglas Seals | Pavel Goldstein | University of Colorado at Boulder | University of Colorado, Boulder

Active Ingredients

Drugs in Phase 4 Trials (3)

beetroot juice (1 trial)

metoprolol (lopressor) (2 trials)

nebivolol (bystolic) (2 trials)

Drugs in Phase 2 Trials (6)

cannabidiol (Epidiolex) (1 trial)

curcumin (2 trials)

fisetin (1 trial)

nicotinamide (2 trials)

sodium nitrite (2 trials)

ubiquinone (2 trials)

Drugs in Phase 1 Trials (3)

atomoxetine (strattera) (1 trial)

attenuated measles vaccine - Edmonston strain (rubeovax) (1 trial)

oxytocin (syntocinon) (1 trial)

Drugs in Other Trials (3)

7-methylxanthine (1 trial)

melatonin (1 trial)

trehalose (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Cognitive Dysfunction (Phase 2)

Hypertension (Phase 2)

Kidney Diseases (Phase 4)

Measles (Phase 1)

Prehypertension (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 18
# of Trial APIs: 15